A Study to Evaluate the Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
Study Details
Study Description
Brief Summary
To demonstrate the safety and tolerability of subcutaneously administered interleukin-2 (IL-2) plus antiretrovirals in patients with HIV infection and CD4 counts of 350 cells/mm3 or more. To demonstrate the immunological efficacy of subcutaneous IL-2 therapy plus antiretroviral therapy relative to antiretroviral therapy alone.
IL-2, given through injection under the skin, in combination with anti-HIV therapy can increase CD4 cell counts. This study examines 3 doses of IL-2 in order to determine the safest and most effective dose to use.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 2 |
Detailed Description
Interleukin-2 administered subcutaneously, in combination with antiretrovirals, results in increases in CD4+ cell count that might impact upon HIV disease progression. A Phase III trial involving large numbers of HIV-positive patients is the next step in the development process. To develop appropriate clinical experience with the combination, this Phase II trial will allow administration of IL-2 plus antiretroviral therapy to a small number of patients in sites being considered for the Phase III trial.
Patients are randomized to control therapy with antiretrovirals alone (36 patients) or antiretrovirals plus IL-2 given subcutaneously every 12 hours for 5 days every 8 weeks. Three doses of IL-2 are studied, with 12 patients evaluated at each dose.
If at least 9 of the first 12 patients complete the 5-day dosing period without dose-limiting toxicities, the next 12 patients randomized are treated with the next higher dose; if this dose is tolerated, the last 12 patients randomized receive the highest study dose. Patients enrolled at the first two doses of IL-2 who complete three courses have their dose escalated to a maximum of the highest dose.
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria
You may be eligible for this study if you:
-
Are HIV-positive.
-
Have a CD4 cell count greater than or equal to 300 cells/mm3.
-
Are at least 18.
-
Have been on antiretroviral therapy for at least 7 days prior to study entry.
Exclusion Criteria
You will not be eligible for this study if you:
-
Abuse alcohol or drugs, or have any serious psychiatric or medical illnesses that would affect your safety or ability to complete the study.
-
Have a history of cancer (other than Kaposi's sarcoma), an AIDS-defining illness, a central nervous system (CNS) abnormality, or an autoimmune/inflammatory disease.
-
Are pregnant or breast-feeding.
-
Have ever received IL-2.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Hospital de Clinicas 'Jose de San Martin' C601-040 CRS | Ciudad de Buenos Aires | Buenos Aires | Argentina | |
2 | Hospital F.J. Muniz C601-050 CRS | Ciudad de Buenos Aires | Buenos Aires | Argentina | |
3 | Hospital General de Agudos J.M. Ramos Mejia CPCRA CRS | Ciudad de Buenos Aires | Buenos Aires | Argentina | |
4 | Hospital Italiano de Buenos Aires C601-020 CRS | Ciudad de Buenos Aires | Buenos Aires | Argentina |
Sponsors and Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
- Study Chair: M Losso,
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRP 021A
- 10467
- SQ 1 ARG
- SQIL-2 Argentina